New Delhi: In an important step to boost India’s clinical research capabilities, the Indian Council of Medical Research (ICMR) signed Memorandums of Agreement (MoAs) with key industry players to conduct first-in-human Phase-1 clinical trials for four promising is therapeutic candidates under its Phase 1 clinical trial network.
As part of this strategic collaboration, ICMR will work with Aurigene Oncology Limited on a small molecule for multiple myeloma, partner with Indian Immunologicals Limited for Zika vaccine development, coordinate seasonal influenza vaccine trials with Mynvax Pvt Ltd and explore CAR-T-CART therapy. Progress with ImmunoACT for chronic lymphocytic leukemia.
Union Health Minister J.P. Nadda lauded the partnership, calling it an important step towards “affordable and accessible state-of-the-art treatment” that strengthens India’s position as a global healthcare innovation leader.
“Establishing a Phase 1 clinical trial infrastructure is a key component in promoting the development of indigenous molecules and cutting-edge treatments. Our vision is to further expand this network, ensuring that India remains at the forefront of developing innovative and affordable healthcare solutions,” said Dr. Rajeev Bahl, Secretary, Department of Health Research and Director General, ICMR, added.
The clinical trial will take place at four premier institutes: KEMH and GSMC in Mumbai, ACTREC in Navi Mumbai, SRM MCH&RC in Kattankulathur and PGIMER in Chandigarh. A central coordinating unit at ICMR headquarters, New Delhi, will oversee operations by ensuring smooth implementation of the trial through dedicated infrastructure and manpower at each site.
